Form 4: Boundless Bio Director Jonathan Lim Granted 24,000 Stock Options

Jonathan E. Lim, a Director at Boundless Bio, Inc., was granted 24,000 stock options with an exercise price of $1.03, vesting over 12 months contingent on continued service.

Summary

• Jonathan E. Lim, a Director of Boundless Bio, Inc. (BOLD), was granted 24,000 stock options.
• The stock options have an exercise price of $1.03 per share.
• The transaction date for this grant was June 23, 2025.
• The options are scheduled to vest in substantially equal monthly installments over the 12 months following June 23, 2025.
• Alternatively, any remaining unvested portion will vest on the date of the next annual meeting of the issuer's stockholders if it occurs prior to June 23, 2026.
• Vesting is subject to Mr. Lim's continued service on the issuer's board of directors through the respective vesting dates.
• The stock options are set to expire on June 22, 2035.
• Following this reported transaction, Mr. Lim beneficially owns 24,000 direct stock options.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation grant to a director, which is generally viewed as a neutral to slightly positive event as it aligns management incentives with shareholder interests. It does not contain any negative operational or financial news.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages the director's continued commitment and service to the board.

Risks

• The value of the granted stock options is contingent on Boundless Bio, Inc.'s stock price exceeding the exercise price of $1.03 in the future.
• The vesting of the options is subject to the director's continued service on the board, meaning unvested options could be forfeited if service ceases prematurely.

Future Outlook

The granted stock options will vest over the 12 months following June 23, 2025, or earlier if the next annual meeting occurs before June 23, 2026, contingent on the director's continued service to the company.

Industry Context

This Form 4 filing reports a standard insider transaction, specifically the grant of equity compensation to a director. Such grants are common practice across industries to align the interests of board members with long-term shareholder value creation.

Related Party Transactions

• Grant of 24,000 stock options to Jonathan E. Lim, a Director of Boundless Bio, Inc., with an exercise price of $1.03, representing a transaction between the company and a related party.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also improved alignment of the director's interests with shareholder value creation.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Jonathan E. Lim's continued service on the board of directors for the stock options to vest according to the schedule.
• Potential future exercise of the vested stock options by Jonathan E. Lim, subject to market conditions and personal financial planning.

Key Dates

Keywords

Boundless Bio, BOLD, Jonathan E. Lim, Stock Option, SEC Form 4, Director Compensation, Equity Grant, Insider Transaction